IFP Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

IFP Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3K	Sell	1,407 -35	-2%	-$60	﹤0.01%	4056
2026 Q1	$2.44K	Sell	1,442 -1	-0.1%	-$4	﹤0.01%	3886
2025 Q4	$7.47K	Buy	1,443 +16	+1%	+$82	﹤0.01%	3221
2025 Q3	$7.45K	Buy	1,427 +23	+2%	+$120	﹤0.01%	3047
2025 Q2	$5.38K	Buy	+1,404	New	+$3.63K	﹤0.01%	3327
2025 Q1	–	Sell	-13	Closed	-$65	–	4306
2024 Q4	$65	Buy	+13	New	+$67	﹤0.01%	4170

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

IFP Advisors's ALDX Position: Q2 2026 in Review

IFP Advisors reduced its Aldeyra Therapeutics (ALDX) stake by 2.4% in Q2 2026, selling an estimated $60 and leaving 1,407 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #4056.

IFP Advisors first reported a position in ALDX in Q4 2024 and has held it in 6 quarters since. The position peaked at $7.47K in Q4 2025. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

IFP Advisors held 1,407 shares of Aldeyra Therapeutics worth $3K as of Q2 2026.
IFP Advisors sold 35 Aldeyra Therapeutics shares in Q2 2026, an estimated $60.
Aldeyra Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4056 holding.
IFP Advisors first reported a position in Aldeyra Therapeutics in Q4 2024 and has held it in 6 quarters since.
IFP Advisors's Aldeyra Therapeutics position peaked at $7.47K in Q4 2025.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.